Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9113190.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
N-methyl-D-aspartate (NMDA) receptors are involved in the development of neuropathic pain. Ketamine, a non-competitive NMDA receptor antagonist, has in several case reports given pain relief but efficacy in dosages tolerated in long-term ketamine treatment is unknown. Another substance with an antagonist action at NMDA receptors and which is approved for peroral administration is dextromethorphan. In a randomized study dextromethorphan was no better than placebo for neuropathic pain but this does not exclude efficacy in selected patients. We report a patient with severe post-herpetic pain resistant to conventional pain treatment which was treated with ketamine for 4 years with good pain relief. The practical application of long-term treatment in different administration forms of ketamine is described. The patient also responded with pain relief in a double-blind trial with oral dextromethorphan.
Medical subject headings
- Dextromethorphan
- Excitatory Amino Acid Antagonists
- Herpes Zoster
- Ketamine
- Neuralgia
- Receptors, N-Methyl-D-Aspartate